{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T18:00:27Z","timestamp":1791568827691,"version":"4.3.4"},"reference-count":48,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2002,4,1]],"date-time":"2002-04-01T00:00:00Z","timestamp":1017619200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Nuclear Medicine"],"published-print":{"date-parts":[[2002,4]]},"DOI":"10.1053\/snuc.2002.31565","type":"journal-article","created":{"date-parts":[[2002,8,25]],"date-time":"2002-08-25T03:46:10Z","timestamp":1030247170000},"page":"148-155","source":"Crossref","is-referenced-by-count":193,"title":["111In- and 90Y-DOTA-Lanreotide: Results and implications of the MAURITIUS trial"],"prefix":"10.1053","volume":"32","author":[{"given":"Irene","family":"Virgolini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Britton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Buscombe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy","family":"Moncayo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Paganelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Riva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/snuc.2002.31565_bib1","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1126\/science.179.4068.77","article-title":"Hypo-thalamic polypeptide that inhibits the secretion of im-munoreactive pituitary growth hormone","volume":"179","author":"Brazeau","year":"1973","journal-title":"Science"},{"key":"10.1053\/snuc.2002.31565_bib2","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1210\/endo.137.5.8612489","article-title":"Somatostatin antisense oligodeoxynucleotide-mediated stimulation of lymphocyte proliferation in culture","volume":"137","author":"Aguila Rodriguez","year":"1996","journal-title":"Endocrinology"},{"key":"10.1053\/snuc.2002.31565_bib3","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1172\/JCI117193","article-title":"Somatostatin analogues suppress the inflammatory reaction in vivo","volume":"93","author":"Karalis","year":"1994","journal-title":"J Clin Invest"},{"key":"10.1053\/snuc.2002.31565_bib4","first-page":"251","article-title":"Cloning and functional characterization of family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract, and kidney","volume":"89","author":"Yamada","year":"1992"},{"key":"10.1053\/snuc.2002.31565_bib5","first-page":"2136","article-title":"Somatostatin receptors, an expanding gene family: Cloning and functional characterization of human SSTR3, a protein coupled to adenylyl cyclase","volume":"6","author":"Yamada","year":"1992","journal-title":"Mol Endocrinol"},{"key":"10.1053\/snuc.2002.31565_bib6","doi-asserted-by":"crossref","first-page":"20422","DOI":"10.1016\/S0021-9258(19)88719-7","article-title":"Cloning of a somatostatin receptor, SSTR3, coupled to adenylylcyclase","volume":"267","author":"Yasuda","year":"1992","journal-title":"J Biol Chem"},{"key":"10.1053\/snuc.2002.31565_bib7","first-page":"894","article-title":"Cloning and expression of a human somatostatin-14-selective receptor variant (somatostatin receptor 4) located on chromosome 20","volume":"43","author":"Demchyschyn","year":"1993","journal-title":"Mol Pharmacol"},{"key":"10.1053\/snuc.2002.31565_bib8","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/0014-5793(93)80124-D","article-title":"A human somatostatin receptor (SSTR3), located on chromosome 22, displays preferential affinity for somatostatin-14 like peptides","volume":"321","author":"Corness","year":"1993","journal-title":"FEBS Lett"},{"key":"10.1053\/snuc.2002.31565_bib9","first-page":"4196","article-title":"Cloning and characterization of a fourth human somatostatin receptor","volume":"90","author":"Rohrer","year":"1993"},{"key":"10.1053\/snuc.2002.31565_bib10","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1056\/NEJM199601253340408","article-title":"Octreotide","volume":"334","author":"Lamberts","year":"1996","journal-title":"N Engl J Meds"},{"key":"10.1053\/snuc.2002.31565_bib11","first-page":"690","article-title":"Cross-competition between vasoactive intestinal peptide and somatostatin for binding to tumor cell membrane receptors","volume":"54","author":"Virgolini","year":"1994","journal-title":"Cancer Res"},{"key":"10.1053\/snuc.2002.31565_bib12","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/S0140-6736(89)91258-0","article-title":"Localization of endocrine-related tumors with radioiodinated analogue of somatostatin","volume":"1","author":"Krenning","year":"1989","journal-title":"Lancet"},{"key":"10.1053\/snuc.2002.31565_bib13","first-page":"652","article-title":"Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]-octreotide in man: Metabolism, dosimetry and comparison with [123I-Tyr-3-]-octreotide","volume":"33","author":"Krenning","year":"1992","journal-title":"J Nucl Med"},{"key":"10.1053\/snuc.2002.31565_bib14","doi-asserted-by":"crossref","first-page":"5138","DOI":"10.1210\/endo.140.11.7126","article-title":"Indium-111-DOTA-lanreotide: A novel tumor diagnostic and therapeutic somatostatin analog","volume":"140","author":"Smith-Jones","year":"1999","journal-title":"Endocrinology"},{"key":"10.1053\/snuc.2002.31565_bib15","first-page":"103(A)","article-title":"Biodistribution of a new chelated somatostatin analogue, [In-111-DOTA-D-Phe1-Tyr3]-octreotide; comparison with [In-111-DTPA-D-Phe-1]-octreotide in humans","volume":"38","author":"Krenning","year":"1997","journal-title":"J Nucl Med"},{"key":"10.1053\/snuc.2002.31565_bib16","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S0140-6736(05)78355-0","article-title":"Yttrium-90-labeled somatostatin-analogue for cancer treatment","volume":"351","author":"Otte","year":"1998","journal-title":"Lancet"},{"key":"10.1053\/snuc.2002.31565_bib17","first-page":"1928","article-title":"Indium-111-DOTA-lanreotide: Biodistribution, safety and radiation absorbed dose tumor patients","volume":"39","author":"Virgolini","year":"1998","journal-title":"J Nucl Med"},{"key":"10.1053\/snuc.2002.31565_bib18","first-page":"2090","article-title":"Response to treatment with 90Y-DOTA-lanreotide of a patient with metastaticgastrinoma","volume":"39","author":"Leimer","year":"1998","journal-title":"J Nucl Med"},{"key":"10.1053\/snuc.2002.31565_bib19","first-page":"153","article-title":"New trends in peptide receptor radioligands","volume":"45","author":"Virgolini","year":"2001","journal-title":"Q J Nucl Med"},{"key":"10.1053\/snuc.2002.31565_bib20","first-page":"884","article-title":"111In\/90Y-DOTA-lanreotide scintigraphy and therapy: Initial clinical results of \u201cMAURITIUS.\u201d","volume":"25","author":"Virgolini","year":"1998","journal-title":"Eur J Nucl Med"},{"key":"10.1053\/snuc.2002.31565_bib21","first-page":"1156","article-title":"Clinical utility of 90Y-DOTA-lanreotide in the treatment of anaplastic or metastatic undifferentiated thyroid carcinoma","volume":"26","author":"Moncayo","year":"2000","journal-title":"Eur J Nucl Med"},{"key":"10.1053\/snuc.2002.31565_bib22","first-page":"1198","article-title":"Use of radiolanreotide to treat somatostatin receptor positive tumors","volume":"28","author":"Buscombe","year":"2001","journal-title":"Eur J Nucl Med"},{"key":"10.1053\/snuc.2002.31565_bib23","first-page":"267","article-title":"Treatment of somatostatin receptor (SSTR) positive tumors with Y-90-DOTA-lenreotide: Preliminary studies","volume":"41","author":"Goldsmith","year":"2001","journal-title":"J Nucl Med"},{"key":"10.1053\/snuc.2002.31565_bib24","first-page":"104","article-title":"Tumor-targeted radionuclide therapy trial design driven by patient dosimetry","volume":"41","author":"De Nardo","year":"2000","journal-title":"J Nucl Med"},{"key":"10.1053\/snuc.2002.31565_bib25","first-page":"36","article-title":"Diagnostic reliability of somatostatin receptor scintigraphy during continuous treatment with different somatostatin analogs","volume":"27","author":"Dorr","year":"1993","journal-title":"Horm Metab Res Suppl"},{"key":"10.1053\/snuc.2002.31565_bib26","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0169-5002(97)00657-0","article-title":"Intensification of 111In-DTPA-octreotide scintigraphy by means of pretreatment with cold octreotide in small cell lung cancer","volume":"17","author":"Soresi","year":"1997","journal-title":"Lung Cancer"},{"key":"10.1053\/snuc.2002.31565_bib27","doi-asserted-by":"crossref","first-page":"477","DOI":"10.3109\/00365517709101835","article-title":"Studies on renal tubular protein reabsorption: Partial and near complete inhibition by certain amino acids","volume":"37","author":"Morgensen","year":"1977","journal-title":"Scand J Clin Lab Invest"},{"issue":"suppl","key":"10.1053\/snuc.2002.31565_bib28","first-page":"236","article-title":"Dose-effect relation for kidney damage after 90Y-DOTA-octreotide therapy","volume":"41","author":"Konijnenberg","year":"2000","journal-title":"J Nucl Med"},{"key":"10.1053\/snuc.2002.31565_bib29","first-page":"1388","article-title":"Inhibition of renal uptake of Indium-111-DTPA-octreotide in vivo","volume":"37","author":"De Jong","year":"1996","journal-title":"J Nucl Med"},{"key":"10.1053\/snuc.2002.31565_bib30","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1038\/bjc.1993.266","article-title":"Aminoacid infusion blocks renal tubular uptake of an indium-labeled somatostatin analog","volume":"67","author":"Hammond","year":"1993","journal-title":"Br J Cancer"},{"key":"10.1053\/snuc.2002.31565_bib31","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1021\/bc9702258","article-title":"Renal metabolism of 111In-DTPA-D-Phel-octreotide in vivo","volume":"9","author":"Akizawa","year":"1998","journal-title":"Bioconjug Chem"},{"issue":"suppl","key":"10.1053\/snuc.2002.31565_bib32","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1159\/000201398","article-title":"Somatostatin receptor: Scintigraphy and radionuclide therapy","volume":"57","author":"Krenning","year":"1996","journal-title":"Digestion"},{"key":"10.1053\/snuc.2002.31565_bib33","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1080\/028418699431465","article-title":"Treatment with high dose [111In-DTPA-D-Phe1]-octreotide in patients with neuroendocrine tumors-evaluation and toxic effects","volume":"38","author":"Tiennsuu Janson","year":"1999","journal-title":"Acta Oncol"},{"key":"10.1053\/snuc.2002.31565_bib34","first-page":"88","article-title":"In situ radiotherapy with 111In pentreotide. State of the art and perspectives","volume":"44","author":"McCarthy","year":"2000","journal-title":"Q J Nucl Med"},{"key":"10.1053\/snuc.2002.31565_bib35","first-page":"267","article-title":"Targeted treatment of disseminated NETs with radiopeptides","volume":"41","author":"Buscombe","year":"2001","journal-title":"J Nucl Med"},{"key":"10.1053\/snuc.2002.31565_bib36","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/00006231-199803000-00013","article-title":"Internalisation of radiolabeled DTPA-octreotide and DOTA-tyr3-octreotide: Peptides for somatostatin receptor-targeted scintigraphy and radionuclide therapy","volume":"19","author":"deJong","year":"1998","journal-title":"Nucl Med Commun"},{"key":"10.1053\/snuc.2002.31565_bib37","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1007\/s002590050476","article-title":"Yttrium-90 DOTATOC: First clinical results","volume":"26","author":"Otte","year":"1999","journal-title":"Eur J Nucl Med"},{"key":"10.1053\/snuc.2002.31565_bib38","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1007\/s002590100490","article-title":"Receptor-mediated radionuclide therapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide","volume":"28","author":"Paganelli","year":"2001","journal-title":"Eur J Nuc Med"},{"issue":"suppl 1","key":"10.1053\/snuc.2002.31565_bib39","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1159\/000051858","article-title":"OctreoTher: Ongoing early clinical development of a somatostatin-receptor-targeted radionuclide antineoplastic therapy","volume":"62","author":"Smith","year":"2000","journal-title":"Digestion"},{"issue":"suppl","key":"10.1053\/snuc.2002.31565_bib40","first-page":"146","article-title":"Clinical value of 90Y-DOTA-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) of neuroendocrine tumor tissue: First phase II study","volume":"41","author":"Waldherr","year":"2000","journal-title":"J Nucl Med"},{"key":"10.1053\/snuc.2002.31565_bib41","first-page":"146","article-title":"Experimental radiopeptide therapy (ERT) with 90Y-DOTA-D-Phe1-Tyr3-octreotide","volume":"41","author":"Traub","year":"2000","journal-title":"J Nucl Med"},{"key":"10.1053\/snuc.2002.31565_bib42","first-page":"111","article-title":"Targeted radiotherapy with 90Y-DOTA-Tyr3-octreotide (90Y-SMT487; OCTREOTHER\u00ae): A phase I study","volume":"41","author":"Valkeman","year":"2000","journal-title":"J Nucl Med"},{"key":"10.1053\/snuc.2002.31565_bib43","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s002590050439","article-title":"Tumour uptake of the radiolabelled somatostatin analogue (DOTA-Tyr3) octreotide is dependent on the peptide amount","volume":"26","author":"De Jong","year":"1999","journal-title":"Eur J Nucl Med"},{"key":"10.1053\/snuc.2002.31565_bib44","first-page":"147","article-title":"Response to radionuclide therapy using 90Y- and 111In-labeled somatosta-tin analogs is dependent on tumor size","volume":"41","author":"De Jong","year":"2000","journal-title":"J Nucl Med"},{"key":"10.1053\/snuc.2002.31565_bib45","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s002590050462","article-title":"Biokinetics and dosimetry in patients administered with In-111-DOTA-Tyr3-octreotide: Implications for internal radiotherapy with Y-90-DOTATOC","volume":"26","author":"Cremonesi","year":"1999","journal-title":"Eur J Nucl Med"},{"key":"10.1053\/snuc.2002.31565_bib46","first-page":"111","article-title":"[DOTA, Tyr3]octreotate, labeled with 177Lu, is most promising for radionuclide therapy of somatostatin receptor-positive tumors","volume":"41","author":"De Jong","year":"2000","journal-title":"J Nucl Med"},{"key":"10.1053\/snuc.2002.31565_bib47","first-page":"31","article-title":"111In-DTPA-Tyr3-octreotate: Comparison with 111In-DTPA-octreotide in patients","volume":"41","author":"Kweekeboom","year":"2000","journal-title":"J Nucl Med"},{"key":"10.1053\/snuc.2002.31565_bib48","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1056\/NEJM200010263431707","article-title":"Graves' disease","volume":"343","author":"Weetman","year":"2000","journal-title":"N Engl J Med"}],"container-title":["Seminars in Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299802800332?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299802800332?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,5,16]],"date-time":"2021-05-16T05:56:44Z","timestamp":1621144604000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001299802800332"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,4]]},"references-count":48,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2002,4]]}},"alternative-id":["S0001299802800332"],"URL":"https:\/\/doi.org\/10.1053\/snuc.2002.31565","relation":{},"ISSN":["0001-2998"],"issn-type":[{"value":"0001-2998","type":"print"}],"subject":[],"published":{"date-parts":[[2002,4]]}}}